These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Perales IJ; San Agustin K; DeAngelo J; Campbell AM Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028 [No Abstract] [Full Text] [Related]
8. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Lindner SM; Fordyce CB; Hellkamp AS; Lokhnygina Y; Piccini JP; Breithardt G; Mahaffey KW; Singer DE; Hacke W; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Becker RC; Fox KA; Patel MR; Circulation; 2017 Mar; 135(10):1001-1003. PubMed ID: 28264892 [No Abstract] [Full Text] [Related]
9. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
10. Global Prospective Safety Analysis of Rivaroxaban. Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ; J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287 [TBL] [Abstract][Full Text] [Related]
11. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Alberts M; Chen YW; Lin JH; Kogan E; Twyman K; Milentijevic D Stroke; 2020 Feb; 51(2):549-555. PubMed ID: 31888412 [TBL] [Abstract][Full Text] [Related]
15. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805 [TBL] [Abstract][Full Text] [Related]
16. Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. Jun JH; Hwang JC JAMA Ophthalmol; 2015 Oct; 133(10):1184-6. PubMed ID: 26111247 [TBL] [Abstract][Full Text] [Related]
17. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR; Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435 [TBL] [Abstract][Full Text] [Related]
18. Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis. Fernandez-Juarez G; Perez JV; Caravaca-Fontán F; Quintana L; Shabaka A; Rodriguez E; Gadola L; de Lorenzo A; Cobo MA; Oliet A; Sierra M; Cobelo C; Iglesias E; Blasco M; Galeano C; Cordon A; Oliva J; Praga M; Clin J Am Soc Nephrol; 2018 Dec; 13(12):1851-1858. PubMed ID: 30397027 [TBL] [Abstract][Full Text] [Related]